| Domain | Established finding | Quantitative evidence | Suggested ontology/identifier | Evidence status/limitations |
|---|---|---:|---|---|
| Disease entity | Otofacial neurodevelopmental syndrome is a recently defined Mendelian disorder linked to ZSCAN10 deficiency | 1 disease-target association in Open Targets (score 0.607) | MONDO:0975705 | Disease appears newly described; cross-resource coverage is still sparse (pqac-00000002, pqac-00000005) |
| Causal gene | The only currently associated gene identified in retrieved disease-level resources is **ZSCAN10** | 1 associated target; 5-7 evidence records depending on source view | ZSCAN10; ENSG00000130182 | Evidence in retrieved materials converges on a single gene, but detailed variant list was not recoverable from available contexts (pqac-00000000, pqac-00000002, pqac-00000005) |
| Foundational report | Primary disease-defining report is **Laugwitz et al., Brain (2024)** | 7 affected individuals reported | PMID:38386308; Brain 2024; DOI/publication details cited in review | Full primary-text patient table/variant appendix not available in retrieved contexts (pqac-00000004) |
| Inheritance | Reported as **biallelic loss-of-function** disorder with **autosomal recessive** inheritance | 7 affected individuals from the foundational cohort | Autosomal recessive; germline inherited disorder | Open Targets also notes one entry as “biallelic, autosomal or pseudoautosomal”; autosomal recessive is the clearer formulation from review-based clinical summary (pqac-00000001, pqac-00000002, pqac-00000005) |
| Variant class | Pathogenic alleles are described as **loss-of-function**, including **frameshift** and **stop-gained/nonsense** classes | High-confidence variant evidence scores ~0.90-0.92 in Open Targets/EVA-backed entries | Loss-of-function variant class | Exact HGVS nomenclature and allele frequencies were not available in retrieved contexts (pqac-00000002, pqac-00000005) |
| Core neurodevelopmental phenotype | **Global developmental delay** is a consistent clinical feature | Described as present consistently across the 7 affected individuals | Suggested HPO term: global developmental delay | No fine-grained severity percentages or developmental testing metrics available from retrieved contexts (pqac-00000001, pqac-00000003) |
| Craniofacial phenotype | **Facial asymmetry** is part of the characteristic phenotype | Reported consistently in the 7 affected individuals | Suggested HPO term: facial asymmetry | Frequency reported qualitatively as consistent; no standardized dysmorphology breakdown available here (pqac-00000001, pqac-00000003) |
| External ear phenotype | **Outer-ear malformations** are characteristic | Reported consistently in the 7 affected individuals | Suggested HPO term: external ear malformation / abnormality of the external ear | Specific malformation subtypes were not available in retrieved contexts (pqac-00000001, pqac-00000003) |
| Inner ear anatomy | **Semicircular-canal dysplasia** documented on cerebral MRI/inner-ear imaging | Present in imaged affected individuals per review summary; exact denominator not stated | Suggested HPO term: semicircular canal dysplasia; UBERON: semicircular canal | Anatomical description is available, but full radiology details and laterality were not recoverable (pqac-00000001, pqac-00000003) |
| Hearing phenotype | **Sensorineural hearing loss (SNHL)** is a major associated feature | **4/5 tested** individuals had confirmed SNHL | Suggested HPO term: sensorineural hearing impairment | Denominator indicates incomplete testing; true frequency among all affected individuals remains uncertain (pqac-00000001, pqac-00000003) |
| Anatomical systems affected | Disorder involves nervous system, craniofacial structures, outer ear, and inner ear/vestibular apparatus | At least 4 organ-system domains implicated by reported phenotype set | Suggested UBERON labels: brain, external ear, inner ear, semicircular canal | Direct cellular pathology for each tissue has not yet been defined in retrieved sources (pqac-00000001, pqac-00000003) |
| Molecular function | ZSCAN10 is a **zinc finger and SCAN domain-containing transcription factor** implicated in control of **embryonic stem-cell pluripotency** | Qualitative functional role, no disease-specific effect size reported | ZSCAN10; transcription factor; pluripotency-related regulator | Disease mechanism beyond this high-level role remains incompletely resolved in available contexts (pqac-00000001, pqac-00000003) |
| Mechanism / pathophysiology | Current understanding supports an upstream defect in transcriptional regulation during development, plausibly affecting neurodevelopment and otic/craniofacial morphogenesis | Evidence is descriptive rather than pathway-quantified | Suggested GO labels: regulation of transcription, stem cell maintenance, developmental process | Review explicitly notes that precise downstream targets remain unknown; no validated disease pathway map retrieved (pqac-00000003) |
| Age at onset / course | Findings are most compatible with **congenital or early-childhood onset neurodevelopmental disorder** | No exact onset ages available in retrieved contexts | Suggested onset label: congenital/infancy/childhood onset | Formal natural-history data, progression rate, and lifespan data unavailable (pqac-00000001, pqac-00000004) |
| Epidemiology | Prevalence and incidence are **unknown** | Only **7 affected individuals** identified in available foundational report | Ultra-rare Mendelian disorder | No population-based studies, registries, or prevalence estimates identified in retrieved contexts (pqac-00000004, pqac-00000005) |
| Population genetics | No founder effect, carrier frequency, penetrance estimate, or ancestry-specific enrichment established from available contexts | Not reported | Not established | These fields remain evidence gaps pending larger cohorts and database curation (pqac-00000004, pqac-00000005) |
| Diagnostics | Most evidence-supported diagnosis is **genomic testing** identifying biallelic ZSCAN10 loss-of-function variants, with phenotypic support from hearing assessment and imaging of inner-ear anomalies | 7 molecularly defined individuals; hearing loss confirmed in 4/5 tested | Molecular diagnosis; ZSCAN10 sequencing; consider exome/genome in neurodevelopmental + hearing-loss workup | No formal disease-specific diagnostic criteria or validated biomarker studies retrieved (pqac-00000001, pqac-00000003, pqac-00000005) |
| Clinical implementation | Broader expert opinion in neurogenetic hearing loss recommends considering neurogenetic diagnosis when hearing loss co-occurs with developmental delay, hypotonia, or regression | Qualitative recommendation | Neurogenetic hearing-loss diagnostic framework | This is expert contextual guidance, not disease-specific management consensus for ZSCAN10 syndrome (pqac-00000001, pqac-00000003) |
| Treatment | **No disease-specific therapy established** in retrieved sources | 0 disease-specific treatments identified | Supportive care only (conceptual) | No pharmacotherapy, gene therapy, trial, or interventional outcome data retrieved (pqac-00000005) |
| Prognosis | **Unknown** from current retrieved evidence | No survival or long-term outcome series identified | Not established | Natural history, mortality, functional outcomes, and quality-of-life metrics are not yet defined (pqac-00000004, pqac-00000005) |
| Environmental / lifestyle factors | No disease-specific environmental, lifestyle, infectious, or gene-environment risk factors established | 0 identified | Not applicable/unknown | Consistent with a rare Mendelian disorder; absence of evidence should not be overinterpreted as evidence of absence (pqac-00000005) |
| Protective factors | No genetic or environmental protective factors identified | 0 identified | Not established | No modifier/protective data available in retrieved contexts (pqac-00000005) |
| Omics / epigenetics | No disease-specific transcriptomic, proteomic, metabolomic, lipidomic, or epigenomic datasets were retrieved | 0 disease-specific omics studies identified in available contexts | Not established | Mechanistic inference is based mainly on known gene function, not disease-specific multi-omics evidence (pqac-00000003, pqac-00000005) |
| Model organisms / natural disease | No disease-specific animal model or naturally occurring non-human disease evidence was retrieved | 0 disease-specific models identified | Not established | Although ZSCAN10 has broader stem-cell biology literature, no syndrome-specific model evidence was available in retrieved contexts (pqac-00000003, pqac-00000005) |


*Table: This table provides an evidence-bound summary of what is currently established versus unknown for otofacial neurodevelopmental syndrome, centered on the 2024 ZSCAN10 cohort report and supporting disease-resource evidence. It is useful for rapid knowledge-base population while clearly separating confirmed findings from gaps.*